CCDM Quality Control & Regulatory Compliance 4 — Questions and Answers
Question 1: An IRB-approved protocol is amended mid-study to add a new secondary endpoint. From a data management QC perspective, which action is MOST important?
- Immediately update all previously collected CRFs to reflect the new endpoint
- Assess the impact on existing eCRF design, edit checks, and data management plan, and document changes (Correct answer)
- Halt data collection until the amendment is approved in all countries
- Notify the FDA before making any system changes
Correct answer: Assess the impact on existing eCRF design, edit checks, and data management plan, and document changes
A protocol amendment requires an impact assessment to determine which data management components (eCRF, edit checks, DMP) must be updated, and all changes must be documented to maintain a clear audit trail.
Question 2: In the context of CCDM, 'data traceability' most accurately refers to:
- The ability to track shipments of clinical trial supplies to investigator sites
- The ability to trace any data point back to its original source document and forward to its final analysis dataset (Correct answer)
- Tracking patient enrollment numbers against protocol targets
- Monitoring the flow of adverse event reports to regulatory authorities
Correct answer: The ability to trace any data point back to its original source document and forward to its final analysis dataset
Data traceability means any value in an analysis dataset can be traced back to the source document and any source data can be traced forward through all transformations to its final analysis representation.
Question 3: A site submits a query response stating 'data confirmed as entered' without providing source documentation. What is the appropriate CDM response?
- Accept the response and close the query to avoid delaying data lock
- Escalate the query and request source documentation to verify the data against original records (Correct answer)
- Automatically correct the data based on clinical judgment
- Report the site to the IRB for non-compliance
Correct answer: Escalate the query and request source documentation to verify the data against original records
A 'data confirmed' response without source documentation is insufficient; the CDM team must request source documentation to verify the data against original records per GCP requirements.
Question 4: Which ICH guideline specifically addresses the structure and content of clinical study reports (CSRs), including data quality documentation requirements?
- ICH E6(R2)
- ICH E9
- ICH E3 (Correct answer)
- ICH E8
Correct answer: ICH E3
ICH E3 provides guidelines on the structure and content of clinical study reports, including requirements for documenting data quality, protocol deviations, and analysis populations.
Question 5: When performing a go/no-go assessment for database lock, the data management team discovers that 2% of critical efficacy fields remain unanswered after final query. Which action is MOST appropriate?
- Proceed with lock since 98% data completeness meets the threshold
- Document the missing data, assess its potential impact on the primary analysis, and determine if imputation is required per the SAP (Correct answer)
- Re-open all subject records and issue new queries to obtain the missing data
- Remove the incomplete subject records from the analysis dataset
Correct answer: Document the missing data, assess its potential impact on the primary analysis, and determine if imputation is required per the SAP
Missing critical data must be documented, its impact on the primary analysis assessed, and handling (including imputation) should follow pre-specified procedures in the Statistical Analysis Plan.
Question 6: Under 21 CFR Part 312.62, sponsors are required to maintain records of which of the following for each study subject?
- Subject payment receipts and travel reimbursements only
- All adverse events regardless of relationship to the investigational product
- Case histories and disposition of the investigational drug, including records of drug accountability (Correct answer)
- Only serious adverse events reported to the FDA
Correct answer: Case histories and disposition of the investigational drug, including records of drug accountability
21 CFR Part 312.62 requires investigators to maintain case histories for each subject and adequate records of the disposition of investigational drugs, including drug accountability records.
Question 7: A clinical data manager is designing QC checks for a lab data reconciliation between the central lab and the eCRF. Which scenario MOST warrants a critical query?
- A 2% difference in lab value due to unit rounding between systems
- A Grade 3 abnormal lab value present in the central lab feed that is absent from the eCRF (Correct answer)
- Different date formats between the two data sources for the same visit
- A small difference in visit window dates between lab and eCRF records
Correct answer: A Grade 3 abnormal lab value present in the central lab feed that is absent from the eCRF
A Grade 3 (severe) abnormal lab value present in the lab feed but missing from the eCRF is a critical safety data discrepancy that could affect subject safety reporting and regulatory compliance.
CCDM Quality Control & Regulatory Compliance 4
An IRB-approved protocol is amended mid-study to add a new secondary endpoint.
From a data management QC perspective, which action is MOST important?